

Long-lasting flea and tick protection that makes a difference
Compliance | Testimonials | Innovation | Safety | Offers | Guarantee





BRAVECTO® QUANTUM offers a groundbreaking solution that helps ensure compliance and protection
DISCOVER A NEW, INNOVATIVE FORMULATION OF A TRUSTED ACTIVE INGREDIENT.

BRAVECTO QUANTUM is the latest innovation in a line of unique solutions
The 4 key differences of BRAVECTO products

Offers an easy transition to life-long extended-duration protection

Extended-duration protection for dogs 6 months and older available as an injectable, chew, or topical dose

With options for 2-month† flea, tick, and heartworm protection and 12-week flea and tick topical protection1-3

BRAVECTO delivers fast-acting, effective protection, killing fleas and ticks within hours of administration1,4-8

Enhanced pet owner compliance
Compliance among pet owners increased with Bravecto, compared with monthly products.10


Pet owners purchase more months of coverage per year with BRAVECTO Chews vs monthly products10
Hear from veterinarians on how BRAVECTO has transformed flea and tick management
See the difference BRAVECTO Chews makes for veterinarians and pet parents.
“As a busy pet parent myself, I know it can be hard to remember to give prevention every month. That’s why I love the convenience of BRAVECTO Chews, as it lasts nearly 3X† longer than one dose of monthly chews.”
Dr. Molly Brinkmann
Veterinarian and Medical Director
The innovative difference in flea and tick protection brought to you by Merck Animal Health

Discover what makes fluralaner different
BRAVECTO (fluralaner) is an isoxazoline, a novel and specific blocker of insect ligand-gated chloride channels.1,2,5,8,11
BRAVECTO is the only isoxazoline that delivers extended duration protection.† This decreases potential gaps in protection and provides greater efficacy in tick and flea control.1,2,5,8
BRAVECTO is proven safe

PROVEN SAFETY
- No known contraindications for BRAVECTO QUANTUM, BRAVECTO Chews for Dogs, BRAVECTO Topical Solution for Dogs and Cats, and BRAVECTO PLUS.1,2,4,5,6
- In field trials, no adverse reactions were observed from the concurrent use of BRAVECTO with other commonly used medications.2,4,5,6
- In margin of safety study, kittens and puppies were dosed at three 8-week intervals.2,4,5,6
DOGS
BRAVECTO Chews for Dogs has been evaluated for use in breeding, pregnant, and lactating female dogs.5 BRAVECTO is safe to use and efficacious in adult dogs and puppies over 6 months of age and weighing 4.4 lbs or greater.5,6 It has been tested and found safe in puppies at least 8 to 9 weeks of age at 5x the clinical dose.5,6,12
CATS
BRAVECTO is safe to use and efficacious in adult cats and kittens over 6 months of age and weighing 2.6 lbs or greater. It has been tested and found safe in kittens at least 11 to 13 weeks of age at 5x the clinical dose.2
For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318.
Ask about the extended-duration difference
Speak with a Merck Animal Health representative for more information about BRAVECTO flea and tick protection for your hospital.
We’re here to answer any questions and help you start prescribing BRAVECTO for the dogs and cats in your care.

The satisfaction difference
We want to make sure your clients receive the results they expect. That’s why we’ve created the BRAVECTO Brand Promise—our way to show that we stand behind each of these innovative products. We are so confident in our BRAVECTO products that if your clients are dissatisfied, we’ll refund the purchase price and provide additional reimbursements. Contact our team of flea and tick control experts to see if your clients qualify for our BRAVECTO Brand Promise. Our team will work with you to ensure that your clients are satisfied.
Offer pet owner savings
BRAVECTO products offer multiple options for longer-lasting protection compared with monthly products. That already makes it a cost-effective option for pet owners. But now, you can help pet owners save even more on flea and tick control with BRAVECTO.

For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318.
This site is intended for veterinary professionals. Visit our website for pet parents.
*BRAVECTO QUANTUM kills adult fleas, prevents flea infestations, and treats and controls ticks (black-legged, American dog tick, and brown dog tick) for 12 months. BRAVECTO QUANTUM also kills lone star ticks for 8 months.
†BRAVECTO kills fleas and prevents flea infestations. BRAVECTO (fluralaner) Chews for Dogs kills ticks (black-legged tick, American dog tick, brown dog tick, and Asian longhorned tick) for 12 weeks. BRAVECTO Chews also kills lone star ticks for 8 weeks. BRAVECTO (fluralaner topical solution) for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks. BRAVECTO Topical Solution for Dogs also kills lone star ticks for 8 weeks. BRAVECTO (fluralaner topical solution) for Cats kills ticks (black-legged tick and Asian longhorned tick) for 12 weeks. BRAVECTO Topical Solution for Cats also kills American dog ticks for 8 weeks.
IMPORTANT SAFETY INFORMATION
BRAVECTO (fluralaner) Chews for Dogs: The most commonly reported adverse reactions include vomiting, lethargy, diarrhea, anorexia and pruritus. In some cases, adverse events have been reported following use in breeding females. BRAVECTO Chews has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. BRAVECTO Chews is not effective against lone star ticks beyond 8 weeks of dosing. Indicated for dogs 6 months of age and older. BRAVECTO 1-MONTH (fluralaner) Chews: The most commonly reported adverse reactions include itching, diarrhea, vomiting, decreased appetite, elevated ALT, lethargy, and weight loss. Not effective against lone star ticks in puppies less than 6 months of age. Indicated for dogs 8 weeks of age and older. BRAVECTO (fluralaner topical solution) for Dogs: The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. BRAVECTO Topical Solution for dogs has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. BRAVECTO Topical Solution for Dogs is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Indicated for dogs 6 months of age and older. BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension) for Dogs: The most commonly reported adverse reactions in a US field study included lethargy, decreased appetite, vomiting, diarrhea, elevated liver enzymes and pruritus. BRAVECTO QUANTUM is not effective against lone star ticks beyond 8 months of dosing. Indicated for dogs 6 months of age and older.
BRAVECTO (fluralaner topical solution) for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO Topical Solution for Cats is not effective against American dog ticks beyond 8 weeks of dosing. BRAVECTO Topical Solution for Cats has not been shown to be effective for 12-weeks’ duration in kittens less than 6 months of age. The safety of BRAVECTO Topical Solution for Cats have not been established in breeding, pregnant and lactating cats. For topical use only. Avoid oral ingestion. Indicated for cats 6 months of age and older. BRAVECTO PLUS (fluralaner and moxidectin topical solution) for Cats: The most commonly reported adverse reactions include vomiting, hair loss, itching, diarrhea, lethargy, dry skin, elevated ALT, and hypersalivation. BRAVECTO PLUS has not been shown to be effective for 2 months in kittens less than 6 months of age. Use with caution in cats that are heartworm positive. The effectiveness of BRAVECTO PLUS to prevent heartworm disease after bathing or water immersion has not been evaluated. The safety of BRAVECTO PLUS have not been established in breeding, pregnant and lactating cats. Indicated for cats 6 months of age and older.
All BRAVECTO products contain fluralaner, which is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders.
.
References
- BRAVECTO QUANTUM. Product label. Merck Animal Health; 2025
- BRAVECTO Topical Solution for Cats. Product label. Merck Animal Health; 2022.
- Freedom of Information Summary, NADA 141-459. Approved July 20, 2016.
- BRAVECTO PLUS. Product label. Merck Animal Health; 2022.
- BRAVECTO Chews for Dogs. Product label. Merck Animal Health; 2022.
- BRAVECTO Topical Solution for Dogs. Product label. Merck Animal Health; 2019.
- Taenzler J, Wengenmayer C, Williams H, et al. Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs. Parasit Vectors. 2014;7:567. doi:10.1186/s13071-014-0567-6
- Wengenmayer C, Williams H, Zschiesche E, et al. The speed of kill of fluralaner (Bravecto™) against Ixodes ricinus ticks on dogs. Parasit Vectors. 2014;7:525. doi:10.1186/s13071-014-0525-3
- Burgio F, Meyer L, Armstrong R. A comparative laboratory trial evaluating the immediate efficacy of fluralaner, afoxolaner, sarolaner and imidacloprid + permethrin against adult Rhipicephalus sanguineus (sensu lato) ticks attached to dogs. Parasit Vectors. 2016;9(1):626. doi:10.1186/s13071-016-1900-z
- Kynetec Heartworm and flea/tick category analysis—PetTrak™ MAT. June 2024.
- Gassel M, Wolf C, Noack S, Williams H, Ilg T. The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity. Insect Biochem Mol Biol. 2014;45:111-124. doi:10.1016/j.ibmb.2013.11.009
- Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner chewable tablets (Bravecto™), a novel systemic antiparasitic drug, in dogs after oral administration. Parasit Vectors. 2014;7:87. doi:10.1186/1756-3305-7-87